U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997276) titled 'Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib' on May 05.
Brief Summary: The purposes of this study are to determine:
* The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.
* How well the study drug is ...